Abstract Purpose: Cyclin-dependent kinase 9 (CDK9) is a transcriptional regulator and
potential therapeutic target for many cancers. Multiple nonselective CDK9 inhibitors have …

Treatment of multiple myeloma (MM) has advanced dramatically in the past two decades.
However, under the conditions of the COVID-19 pandemic, treatment strategies have been …

Abstract Treatment in medical oncology is gradually shifting from the use of nonspecific
chemotherapeutic agents toward an era of novel targeted therapy in which drugs and their …

CDK4 and CDK6 are rarely mutated but are overexpressed or hyperactivated at a very high
frequency in human cancers. By inhibiting CDK4/CDK6 with an exceptionally selective and …

Active research efforts exploring venetoclax combination therapies, as well as new
generation BCL-2 inhibitors are underway. Following the development of venetoclax …

Introduction The last twenty years have introduced new therapeutic agents for multiple
myeloma (MM); these include proteasome inhibitors (PIs), immunomodulatory drugs (IMDs) …

Multiple myeloma (MM) is a hematological malignancy that remains incurable because most
patients will eventually relapse or become refractory to the treatments. Although the …

Introduction: Intracellular molecular inhibitors act by inducing apoptosis due to inhibition of
intracellular proteins like 20S proteasome subunit, histone deacetylases (HDAC's), exportin …

Cell cycle regulators, such as cyclin‐dependent kinases (CDKs), are appealing targets for
multiple myeloma (MM) therapy given the increased proliferative rates of tumour cells in …

Objective: To explore the correlation between clinical factors and the prognosis of multiple
myeloma (MM). Study Design: A cohort study. Place and Duration of Study: At the Third …